TABLE 1.
QBB2‐1 demographics and baseline characteristics by IGA score.
| Characteristics | IGA 2 (mild) | IGA 3,4 (moderate and severe) | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Vehicle | Delgocitinib 0.25% ointment | Delgocitinib 0.5% ointment | Vehicle | Delgocitinib 0.25% ointment | Delgocitinib 0.5% ointment | Vehicle | Delgocitinib 0.25% ointment | Delgocitinib 0.5% ointment | |
| n | 13 | 13 | 14 | 22 | 21 | 20 | 35 | 34 | 34 |
| Sex (n [%]) | |||||||||
| Men | 4 (11.4) | 10 (29.4) | 6 (17.6) | 14 (40.0) | 12 (35.3) | 12 (35.3) | 18 (51.4) | 22 (64.7) | 18 (52.9) |
| Women | 9 (25.7) | 3 (8.8) | 8 (23.5) | 8 (22.9) | 9 (26.5) | 8 (23.5) | 17 (48.6) | 12 (35.3) | 16 (47.1) |
| Age (years, mean ± SD) | 9.2 ± 4.3 | 8.7 ± 3.6 | 6.7 ± 4.9 | 8.3 ± 3.9 | 8.3 ± 4.0 | 9.8 ± 3.7 | 8.6 ± 4.0 | 8.4 ± 3.8 | 8.5 ± 4.4 |
| Duration of AD (years, mean ± SD) | 6.3 ± 4.6 | 5.9 ± 4.6 | 5.6 ± 4.6 | 6.5 ± 4.1 | 6.2 ± 3.8 | 7.4 ± 3.2 | 6.4 ± 4.2 | 6.1 ± 4.0 | 6.6 ± 3.8 |
| mEASI score BL (mean ± SD) | 8.6 ± 2.9 | 8.6 ± 2.9 | 8.3 ± 2.4 | 12.8 ± 4.9 | 11.6 ± 4.5 | 13.1 ± 4.8 | 11.3 ± 4.7 | 10.5 ± 4.2 | 11.1 ± 4.6 |
| Pretreatment drug (n [%]) | 10 (76.9) | 10 (76.9) | 9 (64.3) | 20 (90.9) | 20 (95.2) | 19 (95.0) | 30 (85.7) | 30 (88.2) | 28 (82.4) |
| Topical corticosteroids (n [%]) | 9 (69.2) | 10 (76.9) | 8 (57.1) | 20 (90.9) | 20 (95.2) | 18 (90.0) | 29 (82.9) | 30 (88.2) | 26 (76.5) |
| Strongest | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Very strong | 2 (15.4) | 0 (0.0) | 0 (0.0) | 5 (22.7) | 3 (14.3) | 4 (20.0) | 7 (20.0) | 3 (8.8) | 4 (11.8) |
| Strong | 7 (53.8) | 6 (46.2) | 4 (28.6) | 10 (45.5) | 13 (61.9) | 7 (33.3) | 17 (48.6) | 19 (55.9) | 11 (32.4) |
| Medium | 7 (53.8) | 7 (53.8) | 7 (50.0) | 15 (68.2) | 13 (61.9) | 14 (70.0) | 22 (62.9) | 20 (58.8) | 21 (61.8) |
| Weak | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 1 (2.9) |
| Tacrolimus ointment (n [%]) | 2 (15.4) | 0 (0.0) | 1 (7.1) | 6 (27.3) | 5 (23.8) | 7 (35.0) | 8 (22.9) | 5 (14.7) | 8 (23.5) |
Abbreviations: AD, atopic dermatitis; BL, baseline; IGA, investigator’s global assessment; mEASI, modified eczema area and severity index; SD, standard deviation.